Latest Ratios: P/E Ratio -5.7x · EV/EBITDA N/A · ROE -99.6%. (2009–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $14M | $14M | $13M | $14M | $89M | $69M | $29M | $28M | $8M | $148M |
| Enterprise Value | $54M | $3M | $13M | $7M | $6M | $81M | $62M | $24M | $24M | $3M | $141M |
| P/E Ratio → | -5.75 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 211.25 | 69.56 | 131.79 | 34.65 | 116.60 |
| P/B Ratio | 3.33 | 1.13 | 7.18 | 1.79 | 1.44 | 6.83 | 10.47 | 5.44 | 2.47 | 1.07 | 12.04 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 189.81 | 57.31 | 111.84 | 14.63 | 110.77 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 94.6% | 75.3% | -110.2% | -134.1% | 11.3% |
| Operating Margin | — | — | — | — | — | — | -1946.7% | -689.3% | -2397.1% | -2288.6% | -386.0% |
| Net Profit Margin | — | — | — | — | — | — | -1935.6% | -662.3% | -2378.6% | -2203.7% | -395.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -99.6% | -99.6% | -136.7% | -101.9% | -156.3% | -135.5% | -107.1% | -32.9% | -53.9% | -51.0% | -49.5% |
| ROA | -82.9% | -82.9% | -97.1% | -81.8% | -134.2% | -105.3% | -77.2% | -31.1% | -51.7% | -48.7% | -43.1% |
| ROIC | -452.3% | -452.3% | -383.2% | -337.3% | -360.8% | -724.9% | — | -58.3% | -77.0% | -101.4% | -82.3% |
| ROCE | -109.6% | -109.6% | -155.0% | -111.8% | -162.9% | -211.8% | -88.4% | -34.2% | -54.4% | -53.0% | -48.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.51 | -0.75 | -0.75 | -0.59 | -1.06 | -0.96 | -0.37 | -0.62 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($11M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.67 | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 12.23 | 21.60 | 21.06 | 19.40 |
| Quick Ratio | 10.67 | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 12.70 | 21.14 | 20.85 | 19.00 |
| Cash Ratio | 10.01 | 10.01 | 0.57 | 2.94 | 3.31 | 5.37 | 4.72 | 10.90 | 20.88 | 20.46 | 18.29 |
| Asset Turnover | — | — | — | — | — | — | 0.03 | 0.07 | 0.02 | 0.03 | 0.10 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 1.99 | 7.85 | 4.52 |
| Days Sales Outstanding | — | — | — | — | — | — | 97.07 | 192.86 | 71.06 | 2.06 | 24.63 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $3M | $3M | $2M | $2M | $1M | $655318 | $478229 | $23810 | $210150 |
Clinical Trial Funding Gap
According to recent financial data, EDSA trades at a price-to-book ratio of 3.85, a multiple that appears disconnected from the company's lack of revenue and suggests investors are pricing in the speculative potential of the EB05 pipeline rather than current fundamental asset value.
The absence of meaningful P/E or P/S multiples highlights that traditional valuation metrics are currently inapplicable to this pre-revenue entity. Investors should monitor whether this premium valuation persists if clinical trial timelines for EB05 continue to face delays, as the current P/B ratio may be vulnerable to significant downward revision.
Based on reported figures, EDSA's ROIC has consistently remained in deep negative territory, reaching -3.1% in 2026Q2, which underscores the substantial capital destruction inherent in funding long-term clinical development without the benefit of commercialized products or operational scale to offset research expenditures.
The persistent negative returns on invested capital indicate that every dollar of equity raised is being consumed by R&D and administrative overhead rather than generating economic value. This trend warrants further investigation into whether the company can achieve a positive inflection point before its current cash reserves are fully exhausted.
As reported in financial statements, the current ratio has fluctuated significantly, dropping to 4.76 in 2026Q2 from higher levels, which suggests that the company's ability to cover short-term obligations is becoming increasingly dependent on the timing of equity raises rather than internal cash generation.
While the current ratio appears superficially healthy, the rapid depletion of cash reserves suggests that the company's liquidity position is highly fragile. Investors should monitor the cash burn rate closely, as the current trajectory implies that the company may face a liquidity crunch if clinical milestones are not met on schedule.
As indicated by peer comparison data, EDSA's valuation metrics often diverge from those of more established biotech firms like ADMA Biologics, which maintains a positive ROE of 39.0%, highlighting the structural disadvantage EDSA faces as a pre-revenue entity compared to peers with commercialized product portfolios.
The gap between EDSA and its peers is not merely temporary but reflects a fundamental difference in business maturity and risk profile. This suggests that EDSA will likely continue to trade at a discount until it can demonstrate a clear path to regulatory approval and commercial revenue generation.
The price-to-book ratio is frequently misapplied to EDSA, as it obscures the reality that the company's primary assets are intangible clinical-stage intellectual property rather than tangible book value, which may lead investors to incorrectly perceive the stock as undervalued based on historical balance sheet metrics.
Investors should instead focus on the cash runway and the probability-weighted net present value of the EB05 and EB01 programs. Relying on P/B ratios in a clinical-stage biotech context ignores the high probability of asset impairment if clinical trials fail, rendering the book value an unreliable indicator of intrinsic worth.
Includes 30+ ratios · 17 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EDSA stock.
Edesa Biotech, Inc.'s current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.
Edesa Biotech, Inc.'s return on equity (ROE) is -99.6%. The historical average is -112.3%.
Based on historical data, Edesa Biotech, Inc. is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.